financetom
Business
financetom
/
Business
/
Hudbay Minerals Maintained at Buy at Stifel Canada Following Copper World Stake Sale; Price Target Raised to C$20
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hudbay Minerals Maintained at Buy at Stifel Canada Following Copper World Stake Sale; Price Target Raised to C$20
Aug 14, 2025 8:40 AM

11:15 AM EDT, 08/14/2025 (MT Newswires) -- Stifel Canada on Thursday maintained its buy rating on the shares of Hudbay Minerals ( HBM ) , while raising its price target to C$20.00 from C$17.00 following the company's second-quarter results and a sale of a stake in its Copper World project to Mitsubishi.

"The $600 million Copper World JV transaction with Mitsubishi Corporation for a 30% minority interest implies 1.6x our P/NAV, and we estimate a $5.20/lb implied copper price for Phase 1 at 10% discount rate. Mitsubishi's initial investment will consist of $420 million in cash at closing and $180 million within 18 months of closing. Mitsubishi will also fund its pro-rata 30% share of future equity capital contributions. We estimate Hudbay's levered project IRR goes to 90% based on PFS capex estimates, validates an attractive long-term value proposition at Copper World, and is a strong endorsement of technical work done at Copper World to date and balance sheet derisking considerations. We reiterate our BUY rating and increase our target price to C$20.00 (from C$17.00)," analyst Ralph Profiti wrote.

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

Price: 15.02, Change: -0.57, Percent Change: -3.63

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
KKR's Bid to Acquire Perpetual Business Segments Rejected
KKR's Bid to Acquire Perpetual Business Segments Rejected
Feb 24, 2025
04:19 AM EST, 02/24/2025 (MT Newswires) -- KKR's (KKR) bid to acquire segments of Perpetual has been rejected, the Australian asset management company said Monday. Perpetual was considering an offer from KKR for its corporate-trust and wealth-management businesses but said it is now terminating the talks in accordance with the recommendations of an independent expert. Perpetual and KKR have engaged...
Update: Tesla, Stellantis, Volkswagen, BYD Under Probe by Italian Regulator Over EV Claims
Update: Tesla, Stellantis, Volkswagen, BYD Under Probe by Italian Regulator Over EV Claims
Feb 24, 2025
04:36 AM EST, 02/24/2025 (MT Newswires) -- (Updates with attribution to the Italian regulator's statement throughout the story.) Tesla (TSLA), Stellantis ( STLA ) , Volkswagen, and BYD are under investigation by Italy's antitrust agency for misleading buyers on battery capabilities of their electric vehicles, the Italian Competition Authority said Friday. The inquiries focus on potentially unfair commercial practices regarding...
Kremlin says it does not see any possibility to renew dialogue with Europe at the moment
Kremlin says it does not see any possibility to renew dialogue with Europe at the moment
Feb 24, 2025
MOSCOW, Feb 24 (Reuters) - Russia does not see any grounds to renew dialogue with Europe for now, Kremlin spokesman Dmitry Peskov said on Monday, hours after the EU agreed on a sixteenth package of sanctions against Russia over the conflict in Ukraine. ...
Takeda Secures EMA Approval for Additional Injection Option for Hereditary Angioedema Drug
Takeda Secures EMA Approval for Additional Injection Option for Hereditary Angioedema Drug
Feb 24, 2025
04:26 AM EST, 02/24/2025 (MT Newswires) -- Takeda Pharmaceutical Co ( TAK ) said Monday that the European Medicines Agency has approved an additional subcutaneous administration option for hereditary angioedema drug TAKHZYRO, or lanadelumab. The drug now comes in a 2 mL pre-filled pen for adolescent and adult patients, the company said. Hereditary angioedema is a rare genetic disease that...
Copyright 2023-2026 - www.financetom.com All Rights Reserved